Abstract
No public abstract is available from the verified source records.
Mohamad Elgozair, Basel Abdelazeem, Ahmad W Haddad, Wassim Abouzeid, Hanin Lataifeh, Arsalaan Asad, Mohanad Elchouemi, Russell Stien
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Hypertrophic Cardiomyopathy
10.1056/nejmra2413445 · 2025
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
10.1161/cir.0000000000001250 · 2024
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction
10.1161/circulationaha.106.644682 · 2006
Atrial Fibrillation in Hypertrophic Cardiomyopathy
10.1016/j.jacadv.2024.101210 · 2024
Clinical Course and Management of Hypertrophic Cardiomyopathy
10.1056/nejmra1710575 · 2018
Ischemic Stroke in Patients With Hypertrophic Cardiomyopathy According to Presence or Absence of Atrial Fibrillation
10.1161/strokeaha.121.034213 · 2022
Prognosis of hypertrophic cardiomyopathy patients with atrial fibrillation: A multicenter cohort study with real-world data
10.1016/j.hrtlng.2026.102790 · 2026
Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: A propensity score-matched cohort
10.1016/j.jtcvs.2018.08.062 · 2019
Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Word of Balance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/j.jacc.2017.06.011 · 2017
Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy
10.1016/j.amjcard.2022.05.032 · 2022
Clinical Significance of Postoperative Atrial Fibrillation in Hypertrophic Cardiomyopathy Patients Undergoing Septal Myectomy
2023
Myectomy versus alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy
10.1093/icvts/ivaa075 · 2020
Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry
10.1161/circulationaha.124.069378 · 2024
Alcohol Septal Ablation versus Septal Myectomy Treatment of Obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis
10.3390/jcm9103062 · 2020
Alcohol septal ablation versus surgical septal myectomy of obstructive hypertrophic cardiomyopathy: systematic review and meta-analysis
10.1093/ejcts/ezad043 · 2023
TriNetX Dataworks-USA: Overview of a Multi-Purpose, De-Identified, Federated Electronic Health Record Real-World Data and Analytics Network and Comparison to the US Census
10.1002/pds.70198 · 2025
A global federated real-world data and analytics platform for research
10.1093/jamiaopen/ooad035 · 2023
Pericardial Effusion Provoking Atrial Fibrillation After Cardiac Surgery: JACC Review Topic of the Week
10.1016/j.jacc.2022.04.029 · 2022
Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data
10.1016/j.jacc.2007.06.054 · 2007
Alcohol and Atrial Fibrillation: A Sobering Review
10.1016/j.jacc.2016.08.074 · 2016
Treatment Strategies for Hypertrophic Cardiomyopathy: Alcohol Septal Ablation and Procedural Step-by-Step Technique
10.1016/j.amjcard.2023.10.064 · 2024
Risk of arrhythmic events after alcohol septal ablation for hypertrophic cardiomyopathy using continuous implantable cardiac monitoring
10.1016/j.hrthm.2020.08.013 · 2021
Altered atrial electrical restitution and heterogeneous sympathetic hyperinnervation in hearts with chronic left ventricular myocardial infarction: implications for atrial fibrillation
10.1161/01.cir.0000080327.32573.7c · 2003
Early and late post-operative arrhythmias after surgical myectomy: 45 years of follow-up
10.1016/j.ijcard.2020.11.055 · 2021
Long-Term Continuous Monitoring of New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting
10.1001/jama.2025.14891 · 2025
Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy: JACC: Heart Failure State-of-the-Art Review
10.1016/j.jchf.2023.04.018 · 2023
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort
10.1016/j.jchf.2023.09.028 · 2024
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
10.1161/circulationaha.124.072445 · 2025
New and recurrent atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy receiving mavacamten
10.1016/j.hrthm.2026.04.033 · 2026
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM
10.1016/j.jchf.2025.03.040 · 2025
Cardiac Myosin Inhibitors and Incident Atrial Fibrillation in Hypertrophic Cardiomyopathy: Systematic Review and Meta-Analysis
10.1111/jce.70317 · 2026
Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy
10.1016/j.jacc.2022.02.032 · 2022
Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score
10.1161/circep.120.009796 · 2021
Subclinical atrial fibrillation and the risk of stroke
10.1056/nejmoa1105575 · 2012
No additional external references are available.